Catalent today announced that Mr. Michael Merges, Director of Strategic Growth, Catalent Biologics Analytical Services, will be presenting at the upcoming WCBP Conference in Washington DC, on Jan. 24 – 26, 2017.
Catalent today announced it has signed an agreement with PATH, an international nonprofit organization and a leader in global health innovation, to advance a project funded by its Malaria Vaccine Initiative (MVI).
Catalent Pharma Solutions celebrated its ground breaking for a new $34 million extension to its state-of-the-art Madison, Wisconsin biologics manufacturing facility on Friday, Oct. 21.
Catalent announced today that it has partnered with Moderna Therapeutics to support near-term clinical GMP mRNA manufacturing efforts for Phase 1/2 clinical studies of the company’s mRNA personalized cancer vaccines.
Catalent Pharma Solutions today announced that its OptiForm® Solution Suite and OptiForm® Solution Suite Bio platforms have won the ‘Excellence in Pharma: Contract Services and Outsourcing’ award at the annual CPhI Pharma Awards.
Catalent and Triphase Accelerator Corporation today announced that Triphase will obtain worldwide rights to further develop Catalent’s proprietary CD22-4AP Antibody-Drug Conjugate (ADC), which has been developed by Catalent’s subsidiary, Redwood Bioscience, Inc.